PDT Partners LLC Has $3.97 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

PDT Partners LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 42.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 522,280 shares of the biotechnology company’s stock after buying an additional 155,510 shares during the quarter. PDT Partners LLC owned 0.25% of BioCryst Pharmaceuticals worth $3,969,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BCRX. Captrust Financial Advisors raised its position in BioCryst Pharmaceuticals by 19.4% in the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,644 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $201,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of BioCryst Pharmaceuticals by 7.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company’s stock worth $388,000 after buying an additional 3,653 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of BioCryst Pharmaceuticals by 472.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after buying an additional 409,938 shares during the period. Finally, FMR LLC boosted its stake in BioCryst Pharmaceuticals by 2.4% in the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after buying an additional 46,110 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, JMP Securities increased their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.50 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a 50-day moving average of $7.61 and a two-hundred day moving average of $7.28. The company has a market cap of $1.55 billion, a PE ratio of -12.29 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the business earned ($0.19) EPS. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.